Dynepo

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
13-03-2008
Tabia za bidhaa Tabia za bidhaa (SPC)
13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma (PAR)
13-03-2008

Viambatanisho vya kazi:

epoetin delta

Inapatikana kutoka:

Shire Pharmaceutical Contracts Limited

ATC kanuni:

B03XA

INN (Jina la Kimataifa):

epoetin delta

Kundi la matibabu:

Antianemic preparations

Eneo la matibabu:

Kidney Failure, Chronic; Anemia

Matibabu dalili:

Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.

Bidhaa muhtasari:

Revision: 9

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2002-03-18

Taarifa za kipeperushi

                                Medicinal product no longer authorised
102
B. PACKAGE LEAFLET
Medicinal product no longer authorised
103
PACKAGE LEAFLET – INFORMATION FOR THE USER
DYNEPO 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 2,000 IU/0.5ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 3,000 IU/0.3ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 4,000 IU/0.4ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 6,000 IU/0.3 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 8,000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
DYNEPO 10,000 IU/0.5ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
Epoetin delta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
-
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet,
please tell your doctor or pharmacist.
IN THIS LEAFLET:
1.
What Dynepo is and what it is used for
2.
Before you take Dynepo
3.
How to take Dynepo
4.
Possible side effects
5.
How to store Dynepo
6.
Further information
1.
WHAT DYNEPO IS AND WHAT IT IS USED FOR
Epoetin delta is a human erythropoietin made by a technology process
called gene-activation, which
uses a human cell line.
Epoetin delta is a hormone which stimulates the production of red
blood cells in the bone marrow. Red
blood cells are very important since they contain haemoglobin, a
protein which distributes oxygen in
your body.
Dynepo is used for treating the symptoms of anaemia (which include
tiredness, weakness and shortness of
breath) associated with chronic renal failure in adult patients
, Anaemia is a blood disorder characterised by
a decrease in red blood cells. Dynepo may be used in patients on
dialysis (a bl
                                
                                Soma hati kamili

Tabia za bidhaa

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Dynepo 1,000 IU/0.5 ml solution for injection in a pre-filled syringe.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Pre-filled syringe containing 1,000 IU per 0.5 ml dose (2,000 IU/ml)
of the active substance epoetin delta.
Epoetin delta is produced in human cells (HT-1080) by gene-activation
technology.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection in a pre-filled syringe.
Clear, colourless and waterlike.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Dynepo is indicated for the treatment of symptomatic anaemia
associated with chronic renal failure (CRF)
in adult patients. It may be used in patients on dialysis and in
patients not on dialysis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Dynepo should be initiated by physicians experienced in
the treatment of anaemia
associated with CRF..
The dosage of Dynepo must be adjusted individually to maintain the
level of haemoglobin within the
target range of 10 to 12g/dl.
Anaemia symptoms and sequelae may vary with age, gender, and overall
burden of disease; a
physician’s evaluation of the individual patient’s clinical course
and condition is necessary. Dynepo
should be administered either subcutaneously or intravenously in order
to increase haemoglobin to not
greater than 12 g/dL (7.5 mmol/L). Subcutaneous use is preferable in
patients who are not receiving
haemodialysis to avoid puncture of peripheral veins.
Due to intra-patient variability, occasional individual haemoglobin
values for a patient above and
below the desired haemoglobin level may be observed. Haemoglobin
variability should be addressed
through dose management, with consideration for the haemoglobin target
range of 10 g/dL
(6.2 mmol/l) to 12g/dL (7.5mmol/l). A sustained haemoglobin level of
greater than 12 g/dL
(7.5 mmol/l) should be avoided; guidance for appropriate dose
adjus
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi epoetin delta

epoetin delta

ATC kanuni B03XA

B03XA

Mzalishaji au wazalishaji wadogowadogo Shire Pharmaceutical Contracts Limited

Shire Pharmaceutical Contracts Limited

INN (Jina la Kimataifa) epoetin delta

epoetin delta

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kibulgaria 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kihispania 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kicheki 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kidenmaki 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kijerumani 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kiestonia 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kigiriki 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kifaransa 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kiitaliano 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kilatvia 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kilithuania 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kihungari 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kimalta 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kiholanzi 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kipolandi 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kireno 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kiromania 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kislovakia 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kislovenia 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kifinlandi 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 13-03-2008
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 13-03-2008
Tabia za bidhaa Tabia za bidhaa Kiswidi 13-03-2008
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 13-03-2008

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari Dynepo epoetin delta

Dynepo epoetin delta

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

Dynepo